Astrazeneca (AZN) Non Operating Income (2009 - 2026)

Astrazeneca (AZN) has reported Non Operating Income for 17 consecutive years, with -$3.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income fell 10.54% year-over-year to -$3.5 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 140.35% YoY), while the FY2025 annual figure was $1.3 billion, up 3.89% from the prior year.
• Non Operating Income came in at -$3.5 billion for Q1 2026 at Astrazeneca, down from $349.0 million in the prior quarter.
• The five-year high for Non Operating Income was $3.8 billion in Q2 2025, with the low at -$7.9 billion in Q4 2023.
• Average Non Operating Income over 5 years is -$896.2 million, with a median of $293.0 million recorded in 2022.
• The largest YoY upside for Non Operating Income was 1014.33% in 2023 against a maximum downside of 918.5% in 2023.
• Year by year, Non Operating Income stood at $293.0 million in 2022, then sank by 2783.28% to -$7.9 billion in 2023, then surged by 104.64% to $365.0 million in 2024, then dropped by 4.38% to $349.0 million in 2025, then tumbled by 1100.57% to -$3.5 billion in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$3.5 billion, $349.0 million, and $349.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.